Table 2.
Number (n) of users of the most commonly used drugs classified as P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP) substrates (S) or inhibitors (I) in the P‐pg/BCRP polytherapy group
Drug | n | P‐gp transporter substrate/inhibitor | BCRP transporter substrate/inhibitor |
---|---|---|---|
Cetirizine | 3242 | S, I | |
Progesterone | 2985 | I | |
Oestradiol (17‐β) | 2813 | I | |
Fluticasone (nasal) | 2765 | S | |
Azithromycin | 2369 | S, I | |
Fluticasone (inhalation) | 1976 | S | |
Budesonide (inhalation) | 1955 | S | |
Prednisolone | 1893 | S | |
Citalopram | 1835 | S, I | |
Diclofenac | 1426 | S, I | |
Omeprazole | 1202 | S, I | I |
Pantoprazole | 1137 | S, I | S, I |
Loratadine | 1028 | S | |
Roxithromycin | 1020 | S, I | |
Desloratadine (descarboethoxyloratadine) | 973 | S | |
Clarithromycin | 805 | S, I | |
Levocetirizine ((R)‐cetirizine) | 787 | S | |
Sertraline | 757 | I | |
Propranol | 749 | I | |
Sulfasalazine | 741 | S | S, I |
Montelukast | 725 | I | |
Quetiapine | 717 | I | |
Ranitidine | 717 | S | |
Lansoprazole | 715 | S, I | I |
Metformin | 710 | S | S |
Erythromycin | 586 | S, I | S |
Prednisone | 537 | S | |
Ciprofloxacin | 469 | S | S |
Methylprednisolone | 458 | S | I |
Etoricoxib | 449 | I |